Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial
Study Details
Study Description
Brief Summary
Approximately 20 Study Sites will participate over total 24 months. Study population will consist of adults age 22 or over, reporting overactive bladder (OAB) symptoms for at least 3 months.
Primary Study Objectives:
-
To assess efficacy of the StimRouter stimulation in improving OAB symptoms of urgency and frequency as measured by Patient Voiding Diary when targeting the posterior tibial nerve
-
To assess safety of the StimRouter therapy for the indication of OAB
Secondary Study Objective:
To evaluate efficacy of the StimRouter therapy in addressing urinary urge incontinence as measured by the Patient Voiding Diary
Study Design is prospective, multi-center, randomized, double-blinded
Primary Endpoint:
The primary efficacy endpoint will be the difference between the investigational and control groups in proportion of responders, where Responder is defined as having ≥50% improvement in average voiding frequency above the normal value of 8 (those returning to normal voiding based on 7-day average voids/leak episodes < 9, will be categorized as achieving half or more reduction) AND having ≥50% improvement in average number of moderate to severe urgency episodes, at approximately three months after programming.
Secondary Endpoint:
Secondary endpoint will be the difference between the investigational and control groups in proportion of patients with reduction by half or more in urinary urge incontinence as measured by the average number of urge incontinence episodes per day.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Approximately 180 subjects will be enrolled in the Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder study. After signing the informed consent and completing the screening visit, eligible candidates will be asked to (1) stop any OAB medications (including but not limited to anti-muscarinic medication or tricyclic antidepressants (TCA) as well as stabilize dosage and frequency of any concomitant medications for 3 weeks, if applicable, and then (2) complete a daily Patient Voiding Diary for 7 days .
Subjects will then return to the office for baseline review. If all screening and baseline criteria are met, the subject will be enrolled, randomized in a 1:1 ratio into either the "control group" or the "investigational group" and scheduled for implant with the StimRouter device.
After approximately 3 weeks for healing post-implant, study participants will be programmed according to their randomization assignment. All subjects will be instructed to apply stimulation at least 3 days/week for at least 30 minutes/day (i.e., the minimum protocol requirements for device use) for 6 months and to apply stimulation when they anticipate OAB events. Patient Voiding Diaries will be completed by the participants for 7 days prior to each follow-up visit and provided to the office at each follow-up visit. Follow-up visits will occur at Month 1, Month 2, Month 3, Month 5 and Month 6. Each follow-up visit will include the review of subject voiding diaries and the completion of other subject questionnaires for measuring OAB and quality of life assessments. Final follow-up evaluations for all subjects will occur at Month 6.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: StimRouter Treatment The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months. |
Device: StimRouter
The StimRouter System is a neuromodulation system consisting of the following components and accessories:
An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.
An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.
A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.
Other Names:
|
| Sham Comparator: StimRouter Control The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months. |
Device: StimRouter
The StimRouter System is a neuromodulation system consisting of the following components and accessories:
An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.
An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.
A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- 1) Patient Voiding Diary [Baseline, Month 3]
The daily Patient Voiding Diary is a self-reported record and it includes how frequently the patient intentionally urinates during the day (frequency) and is awakened to urinate at night (nighttime void frequency), amount voided, number of urgency episodes, voids with moderate to severe urgency, urinary urge incontinence episodes and the degree of urgency to urinate. The 7-day daily Patient Voiding Diary will be assessed at baseline and at approximately 3 months after programming to measure total number of voids (frequency) and voids with moderate-to-severe urgency.The average for each of the seven-day periods will be calculated and compared.
- Adverse Events reported cumulatively throughout study [Baseline through Month 6]
Occurrence of anticipated and unanticipated adverse events will be documented, accumulated and reported for the duration of the study
Secondary Outcome Measures
- Seven-Day Patient Voiding Diary [Baseline, Month 3]
The 7-day daily Patient Voiding Diary will be assessed at baseline and at approximately 3 months after programming to measure urinary urge incontinence episodes.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female age ≥22 years and competent to provide consent
-
Minimum 3 months of self-reported OAB symptoms
-
A mean score of ≥4.0 on the OAB-q symptom questions 1-8
-
Diagnosis of OAB with Overactive Bladder Symptom Score (OABSS) ≥ 8.0
-
Average urinary frequency of ≥ 10 daily voids associated with urgency
-
Able to tolerate and sense tibial nerve stimulation
-
Willing to discontinue OAB and/or tricyclic antidepressant (TCA) medications for 3 weeks prior to the implant and for the entire study period and not to change dosages/frequency of all others for 3 weeks prior to the implant
-
Failed/inadequate response to first- and second-line therapy for OAB
-
Body mass index (BMI) < 31 or investigator does not expect BMI to interfere with ability to place the implant or negatively impact healing at implant site
-
Able to toilet self and have and maintain good personal hygiene
-
Able to utilize the StimRouter system independently
-
Negative urine dipstick result (no UTI detected)
-
If female of child-bearing age, willing to use a medically-acceptable method of contraception for the duration of the study (e.g. oral contraceptives, condoms, shot, patch, etc.)
-
Able to provide clear, thoughtful responses to questions and questionnaires
-
Willing to visit office for device programming and clinical evaluations at 1, 2, 3, 5 and 6 months after starting external device usage
-
Willing to complete a Patient Voiding Diary for 7 consecutive days prior to implant and 7 consecutive days before each follow-up visit, with moderate to severe urge component at Baseline
Exclusion Criteria:
-
Neurogenic bladder
-
Urinary tract mechanical obstruction including but not limited to Benign Prostatic Hyperplasia (BPH), treated or untreated, with ongoing significant obstruction
-
Treatment of bladder or pelvic floor dysfunction with botulinum toxin (Botox ®) or surgery in past 12 months
-
Urinary tract, bladder or vaginal infection or inflammation
-
More than minimal level of stress incontinence or mixed incontinence with stress component likely to confound study outcome
-
Type I diabetes or uncontrolled Type II diabetes
-
Allergy to local anesthetic or adhesives
-
Bleeding disorder or on an anticoagulant that cannot be stopped for 3 days before the implant
-
Pregnant, lactating, planning to become pregnant, given birth in the past 12 months, or female of child-bearing potential and not practicing a medically-approved method of birth control
-
Skin lesions or compromised skin at the implant or stimulation site
-
Use of investigational drug or device therapy or participation in any study involving or impacting gynecologic, urinary or renal function within past 4 weeks
-
Implanted neurostimulator, pacemaker, or defibrillator
-
Current use of TENS in pelvic region, back or leg
-
Current or prior use of electrical stimulation therapy for OAB (e.g. PTNS, sacral nerve stimulation, pelvic floor muscle stimulation or biofeedback)
-
Metallic implant below knee, within 6 inches of proposed site for implanted lead
-
Prior vaginal mesh or similar surgery that has not abolished stress incontinence, intravaginal pessaries, or other evidence of stress incontinence significant enough to confound study
-
Requirement for serial MRIs
-
Presence of a documented condition or abnormality that could compromise the safety of the patient
-
Life expectancy of less than 1 year
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Del Sol Research | Tucson | Arizona | United States | 85710 |
| 2 | Kaiser Permanente Reserach | Irvine | California | United States | 92618 |
| 3 | University of Southern California | Los Angeles | California | United States | 90089 |
| 4 | Providence St. John's Health Center | Santa Monica | California | United States | 90404 |
| 5 | Skyline Urology | Sherman Oaks | California | United States | 91411 |
| 6 | Barrett Cowan, MD, Urology Associates | Englewood | Colorado | United States | 80113 |
| 7 | Clinical Research Center of Florida | Pompano Beach | Florida | United States | 33060 |
| 8 | Meridian Clinical Research, LLC/Urology Associates Savannah | Savannah | Georgia | United States | 31405 |
| 9 | Comprehensive Urologic Care | Barrington | Illinois | United States | 60010 |
| 10 | Sheldon Freedman, MD LTD | Las Vegas | Nevada | United States | 89144 |
| 11 | University of North Carolina Urogynecology | Chapel Hill | North Carolina | United States | 27514 |
| 12 | Cleveland Clinic Glickman Urologic and Kidney Institute | Cleveland | Ohio | United States | 44195 |
| 13 | Basel Hassoun | Oklahoma City | Oklahoma | United States | 73120 |
| 14 | Michael England, MD, Texas Health Care | Fort Worth | Texas | United States | 76104 |
| 15 | Michael DeBakey VA Med Ctr | Houston | Texas | United States | 77030 |
| 16 | Northern Alberta Urology Center | Edmonton | Alberta | Canada | T6G1Z1 |
| 17 | Silverado Research, Inc | Victoria | British Columbia | Canada | V8T2C1 |
| 18 | Toronto Western Hospital | Toronto | Ontario | Canada | M5T258 |
| 19 | University of Sherbrooke | Sherbrooke | Quebec | Canada | J1H 5N4 |
Sponsors and Collaborators
- Bioness Inc
Investigators
- Study Chair: Keith McBride, Bioness Inc
- Principal Investigator: Howard Goldman, MD, The Cleveland Clinic
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CP-STMR-OAB-002